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Summary 
To determine the functional importance of Ras in transformation by Abl oncogenes, we used 
a genetic approach to measure the effect of impaired Ras activity on the ability of Bcr-Abl or 
v-Abl to transform cells. Expression of the catalytic domain of the GTPase activating protein 
for Ras (Gap C terminus) impaired soft agar colony formation by fibroblasts expressing v-Abl 
or Bcr-Abl by 70-80%.  To test Ras function in a model that more closely resembles clinical 
diseases involving Bcr-Abl, double gene retroviruses expressing Bcr-Abl paired with the Gap C 
terminus  or dominant negative Ras  were introduced into  naive mouse bone marrow cells. 
Transformation by Bcr-Abl was completely blocked in both situations. Coexpression of normal 
c-H-Ras accelerated  the transforming activity of Bcr-Abl. These findings show that Ras activation 
is essential for the leukemogenic activity of Abl oncogenes in two distinct model systems. The 
results genetically define a connection between the Bcr-Abl cytoplasmic tyrosine kinase and Ras 
and add to the accumulating evidence that deregulation  of Ras is a central event in the genesis 
of a number of molecularly distinct forms of human myeloid leukemia. 
T 
he Ras family of G-proteins plays a central role in relaying 
growth stimulatory signals from outside the cell to the 
nucleus. Mutations in Ras which disrupt  this  normal sig- 
naling pathway lead to deregulated growth and cancer. Surveys 
of oncogene abnormalities  in human leukemia have found 
a high frequency of activating Ras mutations in acute my- 
doid leukemias  (AML) and myelodysplastic  syndromes (MDS), 
particularly those of the chronic myelomonocytic  leukemia 
(CMML) subtype (1). Ras mutations are also common in pa- 
tients with chronic myelogenous leukemia (CML 1) who lack 
the Bcr-Abl fusion gene (2). These findings suggest that Ras 
mutations are a common feature of myeloid leukemias. A 
notable exception to this trend is the absence of Ras muta- 
tions in Bcr-Abl-positive CML (2, 3). 
One explanation for this apparent paradox is that Ras is 
regulated in an abnormal fashion in CML ceils. Ras is acti- 
vated by stimulatory GDP/GTP exchange molecules such as 
Sos (4, 5) which convert P,  as from its inactive GDP-bound 
state to its active GTP-bound state. Active Ras can bind and 
target the cytoplasmic Raf kinase to the cell membrane, where 
a kinase cascade involving Mek and mitogen-activated  pro- 
tein (MAP) kinase is propagated (6, 7). Negative control of 
Ras is mediated by inhibitory GTPase-activating molecules 
1 Abbreviations used in this paper: CML, chronic  myelogenous leukemia; 
TK, thymidine kinase. 
such as RasGap and neurofibromin  (NF-1), which convert 
Ras back to its inactive state. 
Philadelphia chromosome-positive CML is characterized 
by the tumor-spedfic t(9,22) translocation which creates the 
cytoplasmic Bcr-Abl tyrosine kinase (TK) oncogene. Bcr-Abl 
transforms fibroblasts and hematopoietic cells in culture and 
produces leukemias in mice (recently reviewed in 8). Muta- 
tional analysis has defined several requirements within Bcr- 
Abl for fibroblast transformation.  These include on oligo- 
merization domain within Bcr (9), a Grb-2 binding site in 
Bcr (10), the SH2 domain (11), a catalytically active kinase 
domain (12), the major site of tyrosine autophosphorylation 
(12), and an actin binding domain in the Abl COOH ter- 
minus (13). Dominant negative experiments have shown that 
the c-My: transcription  factor is required for Bcr-Abl trans- 
formation (14). A connection between My: and SH2 domain 
of Bcr-Abl is suggested by the observation that overexpres- 
sion of c-My: specifically restores transforming activity to 
the inactive SH2 mutant (11). The results from complemen- 
tation experiments such as these define at least two indepen- 
dent pathways required for Bcr-Abl transformation. 
Is Ras part of one of these pathways? Studies of the Ras 
protein in cells expressing Bcr-Abl suggest abnormal levels 
of activation because a greater than normal proportion of Ras 
is bound to GTP (15). Several  molecules which can affect Ras 
activity, such as RasGap (16), Grb-2 (10, 17), Shc (18), and 
Crk-L (19), can bind Bcr-Abl. Mutagenesis experiments show 
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forming activity (10).  In this report we have used a genetic 
approach to evaluate directly if Ras is essential for this trans- 
formation signal.  Interruption of Ras function by overexpres- 
sion of the catalytic domain of RasGap or of dominant nega- 
tive c-H-Ras impairs  the transforming  activity of Bcr-Abl 
and v-Abl in fibroblasts and bone marrow cells. The results 
show that Ras is required for the oncogenic activity of Abl 
oncogenes and suggest that Ras activity is essential for human 
CML. Together with the high frequency of activating Ras 
mutations in AML and MDS, abnormal Ras activity appears 
to be a common theme in multiple types of human myeloid 
malignancies. 
Materials  and  Methods 
Retroviral Plasmids and Preparation of Virus Stocks.  cDNAs en- 
coding the Gap C terminus (provided by Jeff DeClue and Doug 
Lowy, National Institutes of Health, Bethesda, ME)), c-H-gas and 
the dominant negative Ash 17 c-H-gas mutant (provided by Simon 
Cook, Onyx Phamaceuticals, Richmond,  CA) were subcloned into 
the pSRalphaMSVtkNeo  retrovirus vector (20) after addition of 
EcoRI linkers. For bone marrow experiments, the pSRctMSVtk- 
Neo vector was modified to allow simultaneous expression of two 
genes from a single retrovirus.  First,  the tkNeo cassette was re- 
moved by digestion with ClaI. Secondary HindIlI and ClaI sites 
in the backbone of the plasmid were destroyed, creating the vector 
pSRceMSV with unique  cloning  sites for EcoRI, HindIlI,  and 
ClaI within the LTRs. To provide an internal promoter, the HindIII 
site was changed to Notl and sequences encoding the TK promo- 
ter were subcloned into the Notl site. Gap C terminus, c-H-gas, 
Ash  17 Ras,  or Neo were  subcloned into  the upstream  EcoRl 
site, and p185  s'-Abl was subcloned into  the downstream  ClaI site 
(see Fig. 4). 
With the exception of v-Mos, all retrovirus stocks were prepared 
by transient  transfection of Cos-7 cell using CaCI2 as described 
previously (20). V-mos retrovirus was obtained from a rat-1 fibro- 
blast producer cell line (14). For retroviruses expressing Bcr-Abl or 
v-Abl, titers were determined  indirectly by measuring Bcr-Abl or 
v-Abl protein expression 48 h after infection of NIH3T3 cells by 
immunoblot or immunohistochemistry. 
Transformation  Assays.  The rat-I/Gap C terminus cell line was 
generated by infection of rata fibroblasts with helper-free retrovirus 
followed by selection in G418 (0.5 mg/ml) for 2-3 wk. Cells were 
maintained continuously in G418 to prevent the outgrowth of cells 
that might delete the retrovirus construct. Transformation by v-Abl 
and Bcr-Abl was measured using a soft agar colony assay as de- 
scribed (14). Hematopoietic  cell transformation  assays were per- 
formed using fresh bone marrow  from the tibias and femurs of 
4-wk-old BALB/c mice as described previously (21). 
Protein Analysis.  Expression  of the Gap C terminus protein was 
measured by two-cycle immunoprecipitation  of rat-I/Gap C ter- 
minus cells Labeled with [3SS]methionine with polyclonal rabbit an- 
tisera raised against the full-length Gap protein (kindly provided 
by Bonnee Rubinfeld, Onyx Pharmaceuticals). Bcr-Abl and v-Abl 
protein  expression was  measured by immunoblot  or immuno- 
histochemistry using the pex-5 anti-Abl monoclonal antibody (11). 
Results 
Overexpression of the Catalytic Domain of RasGap in rat-1 
Fibroblasts.  Transformation by Abl oncogenes can be quan- 
titatively measured in a single-step soft agar colony assay using 
rat-1 fibroblasts acutely infected with retroviruses expressing 
either v-Abl or Bcr-Abl (22).  To determine the role of Ras 
in this transformation process, we inhibited Ras function by 
overexpression  of the  GTPase  activating  protein  for  Ras 
(RasGap), thereby maintaining  a greater pool of Ras in the 
inactive GDP bound state. This approach has been previously 
used to inhibit  the transforming  activity of c-H-Ras (23), 
v-Src (24,  25),  and c-Fms (26). 
cDNAs  for the  full-length  bovine RasGap protein  and 
a truncated  form of RasGap (Gap C  terminus)  containing 
the catalytic GTPase activating domain but not the NH2-ter- 
minal SH2 and SH3 domains, were subcloned into the retro- 
virus vector pSRotMSVtkNeo (20).  This vector contains a 
cis-linked G418 resistance gene and allows the generation of 
high titer retrovirus stocks by transient transfection of Cos-7 
cells.  To ensure that  all  cells at risk  for transformation  by 
v-Abl or Bcr-Abl overexpressed a Gap protein,  populations 
of rat-1 fibroblasts infected with RasGap or Gap C terminus 
retrovirus  were derived by G418 selection. 
To verify that the appropriate RasGap protein was expressed 
in the G418 resistant populations, immunoprecipitations were 
performed  on lysates  from cells  labeled with  [3SS]methio- 
nine. The results showed stable expression of the Gap C ter- 
minus protein at a level comparable with that of endogenous 
RasGap (Fig.  1). We were unable to derive similar popula- 
tions overexpressing the full-length RasGap protein despite 
screening three different G418 populations and 10 independent 
clones. One explanation for this result might be a toxic effect 
of constitutive overexpression of full-length RasGap in rat-1 
ceils, although overexpression of full-length RasGap has been 
described in NIH3T3 cells (25). Importantly, overexpression 
of the Gap C terminus showed no toxic effects on cell growth. 
The number of G418 resistant clones recovered after infection 
with Gap C  terminus retrovirus  ("ol0S/ml of supernatant) 
was comparable with control Neo virus of similar titer,  and 
the growth rates of rat-I/Gap C terminus cells and rat-1/Neo 
were comparable (data  not  shown). 
Overexpression of Gap C Terminus Impairs the Transforming 
Activity of Bcr-Abl and v-Abl.  To measure the effect of Gap 
C  terminus overexpression on transformation  by Abl onco- 
genes,  rat-1/Neo  and rat-I/Gap  C  terminus  cells were in- 
fected with retroviruses expressing either v-Abl or Bcr-Abl. 
Retroviruses expressing c-H-Ras, v-Mos, or an empty vector 
containing  only the Neo gene were used as controls.  2  d 
after infection, cells were plated in soft agar, and transforma- 
tion  was measured by comparing  the  number  of colonies 
after 2-3 wk. 
In three independent  experiments,  overexpression of the 
Gap C  terminus  consistently reduced colony formation by 
Bcr-Abl and v-Abl by 70-80%  (Fig.  2 A). Photographs of 
agar plates from a representative assay are shown in Fig.  3. 
rat-1/Neo cells (Fig.  3, top left) and rat-I/Gap  C  terminus 
cells (bottom left) failed  to form colonies in agar after infec- 
tion with control Neo retrovirus. After infection with v-A bl 
retrovirus,  rat-1/Neo cells formed numerous large colonies 
(Fig. 3, top right) whereas rat-I/Gap C terminus cells did not 
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Figure  1.  Expression  of the Gap C terminus in rat-1 fibroblasts. Rat-1 
fibroblasts were infected  with retrovirus  expressing  the Gap C terminus 
and sdected in G418 for 3 wk. Lysates  from Rat-1 cells and rat-I/Gap 
terminal cells labeled for 3 h with [3sS]methionine  were subjected to two 
cycles  of  immunoprecipitation  with Gap antisera  and visualized  by autora- 
diography after SDS-PAGE. A cartoon of the RasGap protein is shown 
below. 
(bottom right). To be sure that both populations were success- 
fully infected with v-Abl retrovirus, anti-Abl immunoblots 
were performed at the time of the cells were plated in soft 
agar.  The results confirmed equivalent levels of v-Abl pro- 
tein expression in both populations (data not  shown). 
We have postulated that the transformation suppression 
activity of the Gap C terminus is due to downregulation of 
Ras. If this is the case, then overexpression of the Gap C ter- 
minus  should  impair  the  transforming activity of normal 
c-H-Ras. In contrast, the Gap C  terminus should not affect 
the transforming activity of oncogenes known to signal  in- 
dependently of Ras. To test this hypothesis, we infected rat- 
1/Neo and rat-I/Gap C terminus cells with retroviruses ex- 
pressing either the normal c-H-Ras gene or the v-Mos serine 
kinase oncogene, which has been previously shown to trans- 
form NIH3T3 cells in a Ras-independent fashion (23, 27). 
Similar to the results with v-Abl and Bcr-Abl, fewer colo- 
nies were seen in rat-i/Gap C  terminus cells after infection 
with c-H-Ras retrovirus compared with the rat-1/Neo con- 
trol. However, there was no difference in colony number in 
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Figure 2.  Expression  of the Gap C terminus impairs the transforming 
activity of v-Abl, Bcr-Abl, and c-H-Ras, but not v-Mos. (A) rat-1/Neo 
and rat-I/Gap  C terminus  cells  were  infected  with retroviruses  expressing 
v-Abl, Bcr-Abl,  c-H-Ras, or v-Mos  and plated in soft agar. Colonies  were 
counted after 2 wk. The average  colony  counts from three experiments 
are shown. (B) Rat-1 cells were infected  with the retrovirus  stock combi- 
nations listed along the left and plated into soft  agar. The average  colony 
numbers from two experiments are shown. 
tion (Fig.  2 A). These results indicate that rat-I/Gap C ter- 
minus cells suppress transformation in a Ras-specific manner 
and support the hypothesis that the mechanism for this effect 
is through downregulation of Ras. 
To be sure that the transformation suppression activity in 
the rat-I/Gap C  terminus cells was due to the Gap C  ter- 
minus protein and not some other mutation acquired during 
G418 selection, we repeated the experiment in a fashion that 
did not require derivation of any cell lines,  rat-1 cells were 
infected simultaneously with two different retrovirus stocks 
expressing either the Gap C  terminus or v-Abl and plated 
directly into soft agar after 48 h. As previously observed using 
the rat-I/Gap C terminus cell lines, fewer colonies were seen 
after simultaneous infection of rat-1 cells with v-Abl and Gap 
C terminus retroviruses as compared with v-Abl and Neo con- 
trol retroviruses (Fig.  2 B). The magnitude of the suppres- 
sive effect of the Gap C  terminus on v-Abl transformation 
was lower than with the rat-I/Gap C  terminus population 
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formation  by v-Abl. Photographs  are shown of representative  soft agar 
plates from v-Abl experiment scored in Fig. 2. Phtes seeded with rat-1/Neo 
cells and rat-I/Gap C terminus cells are shown on the top left and bottom 
left,  respectively. Plates seeded with the same cells after infection  with 
v-Abl retrovirus  are shown  on the top eight  and bottom right. 
because we were unable  to introduce  the Gap  C  terminus 
gene into  every cell  at  risk  for v-Abl transformation. 
Overexpression of Gap C Impairs the Transforming Activity 
of Bcr-Abl in Hematopoietic Cells.  The fibroblast assay is a 
valuable  model  system  for  the  transformation  by Abl on- 
cogenes, but hematopoietic cells are the true target tissue for 
Bcr-Abl in clinical  disease.  To test for genetic dependence of 
Bcr-Abl on Ras in this tissue, we used an in vitro bone marrow 
transformation assay (21). The culture conditions for this assay 
select for the growth of immature progenitor cells which de- 
velop to the pre-B cell stage over a 5-6-wk latent period from 
an initial inoculum of fresh murine bone marrow. If the bone 
marrow is exposed to Bcr-Abl retrovirus before plating,  the 
culture is overtaken by dense outgrowths of pre-B cells within 
2-4 wk. These Bcr-Abl-expressing pre-B cells form tumors 
at  high  frequency in  syngeneic mice. 
TO measure the effect of the Gap C  terminus  on transfor- 
mation by Bcr-Abl in this assay, it was critical to ensure that 
every cell at risk for Bcr-Abl transformation  also received a 
Cap C terminus gene. This experiment required simultaneous 
introduction  of Bcr-Abl and the Gala C  terminus  gene into 
the same cell using a single retrovirus system. To accomplish 
this,  the Bcr-Abl and Gap C  terminus  cDNAs were cloned 
into a vector previously developed by us for studies of Bcr- 
Abl  and  dominant  negative  Myc  (14).  The  plasmid  was 
modified by incorporating  sequences from the pSRc~MSV- 
tkNeo vector (20) which give higher titers after transient  trans- 
fection in Cos-7 cells.  To control for possible effects of the 
upstream gene (Gap C terminus) on expression of the down- 
stream gene (Bcr-Abl), the Gap C terminus plus Bcr-Abl  retro- 
virus was compared to a symmetrically balanced construct 
in which the Neo cDNA was subcloned into the upstream 
position  (Neo plus Bcr-Abl). 
After infection with the retroviruses listed in Fig.  4, the 
nonadherent  cells  from each plate were counted  at  10 and 
21 d. Plates with greater than 5  x  10  s nonadherent cells per 
ml were scored positive. The number of positive plates over 
the total number plated at the 10- and 21-d time points are 
shown. 87% (13/15) of the plates infected with Neo plus Bcr- 
Abl retrovirus or retrovirus  expressing Bcr-Abl alone were 
transformed within 21 d compared with 0/20 infected with 
Gap C terminus plus Bcr-Abl. This result shows that the Gap 
C  terminus  blocks the transforming  activity of Bcr-Abl in 
bone marrow  cells. 
Dominant Negative  Ras Inhibits, Whereas Wild-type  Ras Stimu- 
lates Bone Mamau Transformation by Bcr-Abl.  In addition to 
its role as a negative regulator of Ras, RasGap may also act 
as a downstream effector of Ras (28). Therefore, it is possible 
that the suppressive effect of the Gap C terminus on Bcr-Abl 
transformation  might  result  from  interference  with  a Ras 
effector pathway. To address this issue, we inhibited Ras func- 
tion by a different strategy, using a dominant inhibitory Ras 
mutant  containing  a serine to asparagine mutation  at posi- 
tion  17 (Asn  17 Ras) (27).  This mutant  shows preferential 
a~nity for GDP over GTP due to improper Mg  2+ binding 
and presumably acts as a competitive inhibitor of normal Ras 
by binding  to  guanine  nucleotide  exchange factors (29). 
The murine bone experiments described above were repeated 
using either normal c-H-Ras or the dominant  negative Asn 
17 Ras paired with Bcr-Abl  in the two gene retrovirus system. 
VIRUS 
TRANSFORMED CULTURES 
(#plates with >5xl0SceCs/toted  # of plates) 
10 DAYS  21 DAYS 
ITKI  NEO  I  0/20  0/20 
[TK  I c-t..I.RA$ I  0/4  0/4 
I'rKIBC,-,'.~.  I  3/12  9/11 
TKIBCR'ABL  I  0/4  414 
[-~'~--~  TKIBCR-ABL  I  9/12  10/10 
~-~'~Tq~x~P-~tl  0/20  0/20 
TK  IBGR-ABL  I  0/20  0/20 
Figure  4.  Expression of either the Gap C terminus or dominant nega- 
tive Ras impairs bone marrow transformation  by Bcr-Abl. Mouse bone 
marrow  cells obtained  from the femurs and tibias of BALB/c mice were 
infected with retrovirus expressing the gene combinations  shown on the 
right and seeded into multiple dishes. After 10 and 21 d, the nonadherent 
calls were counted.  Plates with a density  >5  x  10  s cells/ml were scored 
positive for transformation. The transformation frequency of each retrovirus 
at  10 d (column I) and at 21  d (column  2) is shown  as the number  of 
positive plates over the total  number plated. 
310  Dominant  Negative,  Tyrosine Kinase, Signal Transduction As with the Gap C terminus experiments, Asn 17 Ras blocked 
the transforming activity of Bcr-Abl. None of the plates (0/20) 
from bone marrow infected with Asn 17 Ras plus Bcr-Abl 
retrovirus scored positive.  The titers of all retroviruses were 
tested indirectly by measuring Bcr-Abl protein expression after 
infection of NIH3T3 cells. The Asn 17 Ras plus Bcr.Abl and 
Gap C terminus plus Bcr-A  bl retroviruses were of comparable 
titer to the Neo plus Bcr-Abl retrovirus (data not shown). 
Interestingly, coexpression of normal c-H-Ras with Bcr- 
Abl significantly shortened the latency for Bcr-Abl transfor- 
mation. 75% (9/12) of plates infected with c-H-Rasphs Bcr- 
Abl retrovirus scored positive at 10 d compared with 18% 
(3/16)  of plates  from cells  infected with Neo plus Bcr-Abl 
retrovirus (0/4) or Bcr-Abl retrovirus alone (3/12). This re- 
sult was not due to an independent effect ofc-H-Ras because 
none of the plates from bone marrow infected with c-H-Ras 
retrovirus alone scored positive (0/4), even at 3-4 wk. These 
experiments demonstrate that inhibition of Ras with a dom- 
inant negative mutant blocks Bcr-Abi transformation. The 
fact that additional normal c-H-Ras accelerates Bcr-Abl trans- 
forming activity implies that Ras is limiting for the Bcr-Abl 
transformation signal. 
Discuuion 
Studies of a number of different receptor and cytoplasmic 
TKs show a correlation between Ras activation and mito- 
genic activity (30).  However, there have been relatively few 
direct tests of the requirement for Ras for biological activity 
(31). For the Bcr-Abl TK, biochemical studies show an devated 
ratio of active GTP-Ras versus GDP-Ras in cells expressing 
Bcr-Abl (15). A Bcr-Abl mutant which fails to activate tran- 
scription from a Ras-responsive reporter construct in NIH3T3 
calls cannot transform rat-1 fibroblasts (10). Although data 
such as these support a correlation between Ras activation 
and transforming activity by Bcr-Abl, they fail to directly 
test the requirement for Ras in transformation. 
In this work we have used a genetic approach to demon- 
strate directly that Ras is required for the transforming ac- 
tivity of Bcr-Abl. We have impaired Ras function in fibro- 
blasts  and in hematopoietic calls using two strategies that 
affect different sides of the Ras regulatory cycle. Overexpres- 
sion of the COOH  terminal GTPase activating domain of 
RasGap impairs Ras activity by converting active GTP-bound 
Ras to inactive GDP-bound Ras. The result is a higher than 
normal percentage of Ras in the GDP-bound state. The dom- 
inant inhibitory Asn 17 Ras mutant acts as a competitive in- 
hibitor of normal Ras for binding to GDP/GTP exchange 
molecules, thereby preventing normal Ras activation.  In both 
cases, transformation by Bcr-Abl is suppressed. 
Our  findings  are consistent  with  a  recent  report  (32) 
showing that the growth of a CML cell line expressing Bcr- 
Abl is impaired by antisense oligonucleotides directed against 
Ras. One interpretation of these results is that inhibition of 
Ras leads  to generalized growth suppression rather than a 
specific effect on the Bcr-Abl transformation signal. In fact 
the Ash 17 Ras mutant, which is widely used by a number 
of groups to impair Ras activity, is known to suppress normal 
growth in fibroblasts (27).  Our studies of the Gap C  ter- 
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minus mutant in nontransformed cells show that this is not 
the case. High level expression of Gap C  terminus showed 
no toxic effects on cell growth in fibroblasts  or hematopoi- 
etic cells (our unpublished observations). The suppressive ac- 
tivity of the Gap C terminus on transformation was specific 
because it did not impair the transforming activity of a Ras- 
independent gene, v-Mos. 
Our findings suggest that Bcr-Abl activates  an essential 
signaling pathway that flow through Ras. Recent biochem- 
ical experiments showing Bcr-Abl binds to Grb-2 (10,  17) 
provide a potential mechanism for a Bcr-Abl connection to 
Ras. Whether Grb-2 is the critical connection to Ras is not 
clear. Although a Bcr-Abl molecule with a mutation of the 
Grb-2 binding site (Y177) is no longer able to transform rat-1 
fibroblasts,  it does have growth stimulatory activity in he- 
matopoietic cells  (Goga,  A.,  D.  Afar, J.  McLaughlin,  C. 
Sawyers,  and O.  Witte,  unpublished observations).  These 
findings indicate there may be additional pathways from Bcr- 
Abl to Ras, perhaps through other adaptor molecules known 
to.bind Bcr-Abl such as Shc (18) or Crk-L (19). The recent 
identification of interactions between c-Abl and the Crk SH3 
domain provides a potential mechanism for such a pathway 
(33,  34). 
In addition to Ras,  Myc is another protein essential  for 
transformation by Bcr-Abl (14).  How do Ras  and Myc fit 
together in the Bcr-Abl transformation pathway? Comple- 
mentation experiments show that overexpression of oMyc 
specifically restores transforming activity to a Bcr-Abl gene 
rendered inactive due to a mutation in the phosphotyrosine 
binding region of its SH2 domain (11). These experiments 
define a Myc pathway and suggest that the SH2 domain is 
responsible for a signal to Myc, perhaps through its promoter. 
If the Grb-2 binding site in Bcr-Abl is indeed the primary 
connection to Ras, the fact that Myc does not complement 
a Grb-2 binding mutant of Bcr-Abl may indicate that Ras 
and Myc act independently. Further complementation anal- 
ysis is required to sort out these issues. 
Our  findings  support  accumulating evidence that  Ras 
deregulation is a common theme in many types of human 
myeloid leukemia. In AML, MDS, and Bcr-Abl  negative CML, 
point mutations in Ras are common and create a constitu- 
tively active protein. Molecular studies of myeloid leukemias 
which are not associated with Ras mutations, are beginning 
to uncover abnormalities in Ras regulation. Leukemia cells 
from children with juvenile CML, a disease which pheno- 
typically resembles adult CML but is not associated  with a 
Bcr-Abl translocation or with Ras mutations, contain muta- 
tions in both alleles of NF-I (35). Similar to RasGap,  NF-1 
is a negative regulator of Ras.  Loss of function should lead 
to abnormal Ras activation. Our results suggest that Ras ac- 
tivation is also abnormal in adult CML because of constitu- 
tive activation by Bcr-Abl. Through a similar mechanism, 
it appears likely that the fusion protein in patients with t(5,12) 
associated CMML may also activate Ras. This translocation 
fuses the platelet-derived growth factor receptor (PDGFR- 
B) to a novel gene called Tel (36).  Structural characteristics 
predict a receptor TK which is no longer regulated by binding 
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